Second Consecutive Year Of Growth In NME Approvals In The Cards For FDA

It looks to be a good bet that 2009 will mark a second year of growth in new drug approvals: FDA entered the second half of the year with a robust first-half NME approval tally and a well-stocked pipeline of novel agents with user fee goal dates in the remaining months of the year